Imagion Biosystems Ltd has released a press release.
Appendix 4D
Filed with ASX ·
On 6ix: 6ix.com/news/appendix-4d-99
6ix hasn’t read this filing yet.
Imagion Biosystems Ltd. on 6ix
Earlier from Imagion Biosystems
- Half-Year Results Release
- Non-renounceable Entitlement Offer Shortfall
- Imagion to complete the MagSense HER2 Phase 1 Study
- Imagion Announces New CEO
- Results of Non-renounceable Entitlement Offer
Later from Imagion Biosystems
- 2022 R&D Tax Refund
- Imagion presents ovarian cancer data at AACR conference
- Notice of Extraordinary General Meeting/Proxy Form
- Phase 1 Study Closure and Preliminary Performance
- Imagion Announces Positive Results from Phase 1 Study
Follow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems